US-based company Garmin, better known for its GPS and fitness tracking technology, has launched a clinically-proven electrocardiogram (ECG) app for its top smartwatch, the Venu 2 Plus. The app, which has been approved by the US Food and Drug Administration (FDA), aims to help users more closely monitor their heart health by utilizing existing sensors on the watch to record the electric signals produced by users’ hearts.
ECG capabilities have been available on consumer wearables for some time, but the approval process for these tools can be challenging. Garmin’s app, however, has been clinically validated, making it a major addition to the company’s already powerful platform. Eligible users can access the app immediately and record on-demand ECG readings right on the wrist. After thirty seconds, the app will display the heart rhythm results.
The app is capable of analyzing users’ results for potential health concerns such as early signs of atrial fibrillation (AFib). If synced with Garmin Connect, the app will also provide users with a history of their ECG readings, which can then be shared with medical professionals via the smartphone app.
At the moment, the ECG app is only available to users in the US and is only accessible on Venu 2 Plus. However, Garmin has stated that it plans to continue expanding the launch to additional products in the future. Furthermore, the app will be made available to more users as the company meets the necessary regulatory approval in additional regions.
It is important for users to ensure that their device is utilizing the latest version of Garmin Connect to access the ECG app on their Venu 2 Plus. With the ECG app, users can now have more control over their heart health and can easily share their results with medical professionals, making it a valuable tool for those who want to keep a close eye on their heart health.
Related:
